The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

But until then AbbVie has been making the most of Humira’s dominant position in the US inflammatory disease market, with sales increasing nearly 7% in Q1 to more than $3.9 billion.